Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Niche, Lackluster: Two Words That Sum Up 2008 NME Launches

Executive Summary

The year 2008 won't go down as the bleakest for new molecular entity drug launches. After all, FDA did approve 24 novel biologics and new molecular entities in 2008, more than in any of the three years prior
Advertisement

Related Content

The Year Ahead For Generic Drugs: The Calm Before The Storm
A Return Of The Blockbuster, But Can 2009 Launches Live Up To Potential?
Last Gasp Or New Life? 2009’s Novel Products Have Blockbuster Potential
Nektar Starts Major Push In Opioid-Induced Constipation Space
Last Gasp Or New Life? 2009's Novel Products Have Blockbuster Potential
The Return Of The Blockbuster? Stage Is Set For Prasugrel Approval
With Little Product Overlap, Pfizer/Wyeth Commercial Synergies Are Subtle
Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?
Wyeth Finally Cleared For Pristiq Lift-Off, But With Lower Dose
Wyeth Finally Cleared For Pristiq Lift-Off, But With Lower Dose

Topics

Advertisement
UsernamePublicRestriction

Register

PS050535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel